About
Lars Grundemar serves as an Adjunct Professor at Lund University's Department of Pharmacology and holds a LINXS Fellowship within the Integrative Pharmacology and Drug Discovery working group. He currently acts as CEO of Oncorena, spearheading development of breakthrough therapies for metastatic renal cancer, following extensive leadership roles in R&D across global pharmaceutical corporations in Sweden, USA, Switzerland, Italy, and Denmark.
His educational foundation includes an MD and PhD in Pharmacology from Lund University (1991), with doctoral research focused on identifying and characterizing G-protein coupled receptors for neuropeptide transmitters. This clinical pharmacology specialization underpins his transition from fundamental receptor science to oncology therapeutics.
Grundemar's research portfolio demonstrates evolution from molecular pharmacology toward clinical translation, particularly in renal cancer therapeutics. His current structure-based drug design work through LINXS bridges academic pharmacology and industrial drug development, emphasizing neuropeptide receptor mechanisms applied to oncology challenges.
As LINXS IPDD Working Group 1 Member, he contributes to collaborative drug discovery initiatives while leading Oncorena's therapeutic development. His industry experience spans multinational R&D leadership roles, though no formal academic advising or grant management is documented in the source material.
Grundemar maintains active research engagement through Lund University's pharmacology framework and LINXS' collaborative infrastructure, directing industry-academia translational efforts in oncology without dedicated laboratory mentions in the provided text.
